Edwards Lifesciences Corporation (NYSE: EW) announced that new data on patients at intermediate risk for open-heart surgery demonstrated that transcatheter ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Stifel Raises Price Target on Edwards Lifesciences (EW) to $117; Reiterates Buy April 4, 2016 10:33 AM Edwards Lifesciences (EW) Raising Estimates, PT on Better Than Expected Sapien 3 Data - Leerink PartnersApril 4, 2016 7:50 AM BTIG Upgrades Edwards Lifesciences (EW) to BuyApril 4, 2016 7:35 AM Edwards Lifesciences (EW) PT Raised to $98 at Credit Suisse Following Sapien DataApril 4, 2016 7:21 AM Edwards Lifesciences (EW) PT Raised to at Jefferies Following PARTNER II Sapien 3 DataApril 4, 2016 6:45 AM Edwards SAPIEN 3 TAVR Demonstrates Clinical Superiority To Surgery In PARTNER II StudyApril 3, 2016 11:45 AM Edwards SAPIEN XT Valve Meets Primary Endpoint In PARTNER II TrialApril 2, 2016 9:00 AM Edwards Lifesciences (EW) Catalyst: ACC Meeting April 1, 2016 8:24 AM